Wipro enters into four-year strategic alliance with Avesthagen

20 Jun 2022 Evaluate

Wipro and Avesthagen have entered into a four-year strategic alliance, for making Avesthagen’s genetic testing portfolio commercial. The portfolio includes genome panels offering highly specific, disease-centric analysis for conditions including cancers, neurodegenerative diseases, autoimmune disorders and rare disease conditions.

Together, Avesthagen and Wipro will execute the project titled, ‘Cancer Risk Assessed by NGS profiling of Circulating free DNA and RNA for Lung Cancer Project related Genomics Sequencing services.’ The Project will be jointly led by Avesthagen and Wipro where Wipro’s state-of-the-art Lifesciences lab will perform initial processing of the samples, generate data on the latest Next-generation sequencing platforms, compile genomic sequences and analyze detailed molecular information using computational AI/ML based tools.

Wipro is a leading global information technology, consulting and business process services company.

Wipro Share Price

236.70 -3.15 (-1.31%)
30-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
TCS 3125.05
Infosys 1640.45
HCL Tech. 1694.45
Wipro 236.70
Tech Mahindra 1743.30
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×